Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06693908 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

StatusCompleted
PhasePhase 1
Started2025-03-31
View on ClinicalTrials.gov ↗

Amendment history

2026-09-22
Trial completed
Phase changed: Phase 1/2 → Phase 1
2026-07-15
Study Status, Study Design v21
Re-verified, no change to tracked fields
2026-06-30
Study Status, Contacts/Locations v20
Trial status changed: Recruiting → Active, Not Recruiting
Primary completion date2026-07-09→2026-07-13
Completion date2026-08-16→2026-08-18
Study sitesdetails revised at 1 of 1 site
2026-06-04
Study Status, Contacts/Locations, References v19
Primary completion pushed: 2026-06-09 → 2026-07-09
2026-05-15
Study Status v18
Re-verified, no change to tracked fields
2026-04-16
Study Status v17
Primary completion pushed: 2026-05-03 → 2026-06-09
Completion pushed: 2026-06-30 → 2026-08-16
2026-03-20
2 amendments v15-v16
2 re-verifications since 2026-02-20, no change to tracked fields
2026-01-22
Study Status v14
Primary completion date2026-04-03→2026-05-03
Completion date2026-05-06→2026-06-30
2025-12-11
9 amendments v5-v13
9 re-verifications since 2025-04-11, no change to tracked fields
2025-03-13
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Start date2025-02-21→2025-03-31
Study sites0→1
2025-02-14
2 amendments v2-v3
2 re-verifications since 2025-01-15, no change to tracked fields
2024-12-19
Study Status, Study Design v1
PhasePhase 1→Phase 1/2
2024-11-15
Original filing
This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).
Trial Details
NCT Number NCT06693908
Lead Sponsor Genentech, Inc.
Conditions Moderate to Severe Ulcerative Colitis
Enrollment 24 participants
Start Date 2025-03-31
Primary Completion 2026-07-13 (estimated)
Study Completion 2026-08-18 (estimated)
Updated on ClinicalTrials.gov 2026-09-21